Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

June 26, 2019

Imbrium initiates phase 2 study of IMB-115 in insomnia associated with alcohol cessation

Imbrium Therapeutics, an operating subsidiary of Purdue Pharma, is advancing its novel, potentially first-in-class small molecule IMB-115 (previously referred to as IT-1315) to a Phase 2 clinical study following favorable results from Phase 1 studies evaluating the molecule’s safety and tolerability, including its potential for abuse and interaction with alcohol.

Imbrium initiates phase 2 study of IMB-115 in insomnia associated with alcohol cessation